Oral GLP‑1 pills expand access

The FDA has broadened the oral GLP‑1 landscape twice this season: Novo Nordisk won approval for an oral semaglutide tablet for weight loss in December 2025, and on April 1, 2026 the agency cleared Eli Lilly’s once‑daily oral GLP‑1, Foundayo (orforglipron). (prnewswire.com) (fda.gov) GLP‑1 drugs cut appetite and slow stomach emptying by mimicking a gut hormone that signals fullness to the brain. (prnewswire.com) They have produced weight losses measured in double‑digit percentages and reshaped obesity care over the past few years. (clinicaltrials.gov) The two pills reach that same biology by different chemical roads. Semaglutide is a peptide—the same active molecule used in injectables—formulated for oral delivery with an absorption enhancer so measurable amounts cross the gut wall. (clinicaltrials.gov) In its pivotal OASIS‑4 study the 25 mg daily oral semaglutide produced roughly 13–17% mean weight loss at 64 weeks in trial participants who stayed on treatment. (clinicaltrials.gov) Foundayo is a small‑molecule GLP‑1 receptor agonist. The molecule itself is chemically different from peptide GLP‑1 drugs and does not require the same absorption enhancer or the tight food‑and‑water dosing constraints that oral semaglutide carries. (fiercepharma.com) Trial data show substantial placebo‑adjusted weight loss with orforglipron across phase‑3 studies. (ajmc.com) Regulatory context matters here because Foundayo’s clearance used a new FDA fast‑track device: the Commissioner’s National Priority Voucher (CNPV) pilot. The CNPV compresses review timelines to weeks for medicines the agency classifies as aligned with U.S. national priorities. (fda.gov) The FDA says Foundayo was approved 50 days after filing and 294 days before its original PDUFA date—making it the first new molecular entity cleared under the program. (fda.gov) For safety teams those two features—new chemistry and compressed review—change how you prioritize work. Foundayo’s label includes a boxed warning about rodent thyroid C‑cell tumors and lists gastrointestinal adverse reactions consistent with the GLP‑1 class. (pi.lilly.com) The trials were large enough to show efficacy, but a truncated review window and a novel small‑molecule GLP‑1 mean some uncommon or delayed risks will only show up in widespread use. (ajmc.com) Operationally, pharmacovigilance must adapt. Expect heavier reliance on active surveillance: rapid claims‑based signal detection, pre‑specified cohort studies in large electronic health‑record systems, and faster adjudication of serious gastrointestinal, pancreatic, or thyroid events. (ajmc.com) Companies will also need clear post‑market plans to meet both FDA expectations and public scrutiny about the CNPV pathway. (pharmexec.com) This pair of approvals signals a durable regulatory trend: the agency is willing to accelerate access for medicines it deems high priority, even for a crowded class. (fda.gov) The FDA has opened a public hearing and comment period on the CNPV pilot for June 12, 2026, a concrete moment for safety leaders to press for clarity on post‑market expectations and signal‑management standards. (federalregister.gov)